{
    "PROTOCOL SUMMARY": [
        "Protocol Synopsis", 
        "Trial Schema", 
        "Schedule of Activities"
    ],
    "INTRODUCTION": [
        "Purpose of Trial", 
        "Summary of Benefits and Risks"
    ],
    "TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS": [
        "{Primary/Secondary/Exploratory} Objective + Associated Endpoint {and Estimand}"
    ],
    "TRIAL DESIGN": [
        "Description of Trial Design",
        "Rationale for Trial Design",
        "Access to Trial Intervention After End of Trial",
        "Start of Trial and End of Trial"
    ],
    "TRIAL POPULATION": [
        "Selection of Trial Population",
        "Rationale for Trial Population",
        "Inclusion Criteria",
        "Exclusion Criteria",
        "Lifestyle Considerations",
        "Screen Failures"
    ],
    "TRIAL INTERVENTION AND CONCOMITANT THERAPY": [
        "Description of Trial Intervention",
        "Rationale for Trial Intervention",
        "Dosing and Administration",
        "Treatment of Overdose",
        "Preparation, Handling, Storage and Accountability",
        "Participant Assignment, Randomisation and Blinding",
        "Trial Intervention Compliance",
        "Concomitant Therapy"
    ],
    "DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL": [
        "Discontinuation of Trial Intervention",
        "Participant Withdrawal from the Trial",
        "Lost to Follow-Up",
        "Trial Stopping Rules"
    ],
    "TRIAL ASSESSMENTS AND PROCEDURES": [
        "Screening/Baseline Assessments and Procedures",
        "Efficacy Assessments and Procedures",
        "Safety Assessments and Procedures",
        "Adverse Events and Serious Adverse Events",
        "Pregnancy and Postpartum Information",
        "Medical Device Product Complaints for Drug/Device Combination Products",
        "Pharmacokinetics",
        "Genetics",
        "Biomarkers",
        "Immunogenicity Assessments",
        "Medical Resource Utilisation and Health Economics"
    ],
    "STATISTICAL CONSIDERATIONS": [
        "Analysis Sets",
        "Analyses Supporting Primary Objective(s)",
        "Analysis Supporting Secondary Objective(s)",
        "Analysis of Exploratory Objective(s)",
        "Safety Analyses",
        "Other Analyses",
        "Interim Analyses",
        "Sample Size Determination",
        "Protocol Deviations"
    ],
    "GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT": [
        "Regulatory and Ethical Considerations",
        "Committees",
        "Informed Consent Process",
        "Data Protection",
        "Early Site Closure or Trial Termination"
    ],
    "GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE": [
        "Quality Tolerance Limits",
        "Data Quality Assurance",
        "Source Data"
    ],
    "APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS â€“ DEFINITIONS, SEVERITY, AND CAUSALITY": [
        "Further Details and Clarifications on the AE Definition",
        "Further Details and Clarifications on the SAE Definition",
        "Severity",
        "Causality"
    ],
    "APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS": [
        "Contraception and Pregnancy Testing",
        "Clinical Laboratory Tests",
        "Country/Region-Specific Differences",
        "Prior Protocol Amendments"
    ],
    "APPENDIX: GLOSSARY OF TERMS": [],
    "APPENDIX: REFERENCES": []
}